Sumitomo Pharma (4506) investor relations material

Review of recent performance and strategic transition

• Achieved financial targets ahead of schedule, with record-high profits forecasted for FY2025 and strong sales growth in three key products, particularly in North America.

• Completed restructuring in Asia, focusing on core business areas and generating significant earnings from business transfers.

• Transitioning from structural reforms to a full-fledged growth strategy, emphasizing sustainable growth and expanding the product pipeline.

Product and R&D highlights

• ORGOVYX® and GEMTESAⓇ are targeted for substantial revenue growth into the 2030s, with proactive promotional strategies and market share expansion.

• Demonstrated R&D value with progress in universal influenza vaccine, iPS cell-derived therapies, and two oncology compounds (enzomenib and nuvisertib), both receiving regulatory designations and aiming for launches around 2027-2028.

• Building a robust pipeline in oncology, CNS, and regenerative medicine, leveraging advanced platforms and collaborations.

Future growth engines and innovation

• Focusing on hematological malignancies, neurodegenerative diseases, and regenerative medicine as next-generation growth drivers.

• Advancing iPS cell-derived products, with clinical evidence supporting efficacy in Parkinson’s disease and a pipeline targeting additional indications.

• Developing universal influenza and malaria vaccines using proprietary adjuvant technology, with promising clinical and nonclinical results.